Healing & Recovery

Thymosin Alpha-1 is a 28-amino acid immunomodulatory peptide naturally occurring in the thymus gland that has been extensively studied for its ability to enhance and restore immune function. The peptide acts through Toll-like receptors in dendritic cells, promoting T-cell differentiation and maturation, activating natural killer cells, and modulating cytokine production. With over 4,400 subjects enrolled in clinical trials across the United States, Europe, and China, Thymosin Alpha-1 has demonstrated efficacy in treating chronic hepatitis B and C, cancer immunotherapy, sepsis, COVID-19, and as a vaccine adjuvant. The synthetic form, thymalfasin (Zadaxin), has received regulatory approval in over 30 countries for conditions including hepatitis B, hepatocellular carcinoma, and malignant melanoma. However, it is not FDA-approved in the United States, though it received orphan drug designation. Clinical experience involving over 11,000 subjects across more than 30 trials demonstrates a favorable safety profile with only minor, transient side effects, primarily mild injection site reactions. The peptide is typically administered subcutaneously at doses of 0.8-6.4 mg twice weekly.

LL-37 is the sole human member of the cathelicidin family of antimicrobial peptides, derived from the C-terminal fragment of the human cationic antimicrobial protein 18 (hCAP18). This 37-amino acid peptide was identified in the 1990s as a critical component of human innate immunity. LL-37 functions through multiple mechanisms including direct antimicrobial activity via membrane disruption, immunomodulation through regulation of inflammatory responses, chemotaxis of immune cells, lipopolysaccharide neutralization, and promotion of wound healing and angiogenesis. The peptide is expressed in epithelial tissues of the skin, gastrointestinal tract, respiratory tract, and in various leukocytes including neutrophils, monocytes, and lymphocytes. Its expression is regulated by vitamin D, bacterial components, cytokines, and tissue injury signals. Currently, LL-37 is not FDA-approved for therapeutic use and remains available only for research purposes, though phase 1 clinical trials have been completed for melanoma and exploratory studies conducted for COVID-19 and sepsis.

MGF (Mechano Growth Factor) is a splice variant of Insulin-like Growth Factor 1 (IGF-1) that plays a crucial role in muscle repair, tissue regeneration, and neuroprotection. It is produced in response to mechanical stress and muscle damage, activating satellite cells and promoting tissue healing. MGF is also known as IGF-1Ec in humans and IGF-1Eb in rodents, characterized by a unique E domain resulting from alternative splicing of the IGF-1 gene.

TB-500 (Thymosin Beta-4) is a naturally occurring 43-amino acid peptide that functions as the major G-actin-sequestering molecule in mammalian cells. It plays crucial roles in tissue repair, wound healing, and cellular regeneration by regulating cell migration, proliferation, and differentiation. The peptide has demonstrated significant therapeutic potential in multiple clinical applications including dermal wound healing, corneal injuries, dry eye disease, and cardiac tissue repair following myocardial infarction. Phase I and Phase II clinical trials have established its safety profile at various dosing regimens, though it remains unapproved by regulatory agencies. TB-500 is sold on the gray market as a research chemical and is prohibited in competitive sports by the World Anti-Doping Agency due to its performance-enhancing and tissue regeneration properties.

GHK-Cu (glycyl-L-histidyl-L-lysine-copper) is a naturally occurring copper-binding tripeptide first isolated from human plasma in 1973. It functions as a signaling molecule that modulates multiple cellular pathways involved in tissue repair and regeneration. The peptide's concentration in human plasma declines from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60, correlating with decreased regenerative capacity. GHK-Cu works through several mechanisms including copper ion transport, gene expression modulation (affecting over 4,000 human genes), collagen and elastin synthesis stimulation, antioxidant activity via superoxide dismutase enhancement, and growth factor pathway activation. Research demonstrates efficacy in wound healing, skin regeneration, hair follicle stimulation, and anti-inflammatory responses across multiple tissue types. The peptide is not FDA-approved for therapeutic use but is widely used in cosmetic products. It was recently added to FDA's Category 1 bulk substances list for 503A compounding, though not for injectable routes. GHK-Cu is available primarily through compounding pharmacies for research purposes and in topical cosmetic formulations marketed for anti-aging and skin rejuvenation applications.

PEG-MGF is a synthetically modified version of Mechano Growth Factor (MGF), a splice variant of Insulin-like Growth Factor-1 (IGF-1Ec). Through pegylation - the attachment of polyethylene glycol molecules - and the substitution of L-arginine with D-arginine, PEG-MGF achieves dramatically extended stability and half-life compared to native MGF. This peptide plays a crucial role in tissue repair and regeneration by activating satellite cells (muscle stem cells), promoting cellular proliferation, and providing anti-apoptotic effects. PEG-MGF is particularly responsive to mechanical stress and injury, making it a key factor in muscle repair, cardiac protection, bone healing, cartilage regeneration, and neuroprotection.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (sequence: GEPPPGKPADDAGLV) derived from a protective protein found in human gastric juice. The peptide demonstrates pleiotropic biological activity through multiple mechanisms, including stimulation of vascular endothelial growth factor (VEGF) expression and VEGFR2 receptor activation, enhancement of growth hormone receptor expression, activation of the FAK-paxillin pathway for cell migration, and modulation of the nitric oxide system via Src-Caveolin-1-eNOS signaling. Preclinical research in animal models has shown consistent healing effects across diverse tissue types including tendons, ligaments, muscles, bones, gastrointestinal mucosa, and neural tissue. While BPC-157 was tested in Phase I clinical trials for inflammatory bowel disease (PL14736) by Pliva, Croatia, human clinical data remains extremely limited with only one small retrospective study in musculoskeletal pain. The FDA classified BPC-157 as a Category 2 bulk drug substance in 2023, prohibiting compounding due to insufficient safety evidence in humans. The World Anti-Doping Agency (WADA) and major sports organizations ban its use. Despite lack of FDA approval, the peptide is available through gray market channels and increasingly used by clinicians and athletes, raising significant safety and regulatory concerns.

KPV is a tripeptide consisting of lysine-proline-valine, derived from the C-terminal sequence of alpha-melanocyte stimulating hormone (α-MSH). This short peptide exhibits potent anti-inflammatory properties without the pigmentation effects associated with full-length α-MSH. [1][2] The peptide functions by modulating inflammatory pathways, particularly through inhibition of pro-inflammatory cytokines and regulation of NF-κB signaling. Research has demonstrated its ability to reduce inflammation in various tissue types, with particular interest in gastrointestinal applications for inflammatory bowel disease. [3][4] KPV can be administered orally, topically, or via injection, with each route showing different tissue targeting properties. The oral route appears particularly promising for gut-targeted anti-inflammatory effects, while topical application may benefit skin conditions. Research remains largely preclinical, with human clinical trials still limited. [5][6]